Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, October 23, 2018
Eisai: Application Seeking Manufacturing and Marketing Approval in Japan Submitted for Parkinson's Disease Treatment Safinamide
Monday, October 22, 2018
Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan
Friday, October 19, 2018
Eisai: Discovery of Candidate Compound as Potential Treatment for Parkinson's Disease Using iPS Cells
Thursday, October 18, 2018
Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 11th Clinical Trials on Alzheimer's Disease Conference
Wednesday, October 17, 2018
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
Tuesday, October 16, 2018
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Latin America With Eurofarma
Friday, October 12, 2018
Eisai's New Drug Application for Perampanel for Adjunctive Treatment of Partial Onset Seizures Accepted in China
Wednesday, October 10, 2018
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2018 Congress
Friday, October 5, 2018
New Data on Effect of Anti-Obesity Agent BELVIQ on Prevention and Remission of Type 2 Diabetes Presented at The European Association for the Study of Diabetes and Published in The Lancet
Monday, October 1, 2018
Eisai's Fycompa Newly Approved by U.S. FDA as Treatment for Partial-Onset Seizures in Pediatric Patients with Epilepsy

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: